کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
4188703 | 1608290 | 2013 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Desvenlafaxina, un nuevo IRSN para el tratamiento de la depresión mayor: Revisión de la literatura
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
روانپزشکی و بهداشت روانی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Desvenlafaxine (DESV) is a new antidepressant within the group of serotonin-norepinephrine reuptake inhibitors (SNRI). Various controlled clinical trials have demonstrated its efficacy in the treatment of adult patients with a major depressive disorder. These studies have evaluated the efficacy of DESV in doses that varied between 50Â mg and 400Â mg/day. However, the therapeutic dose of DESV has been established at 50Â mg/ day, with no additional therapeutic benefits being observed at higher doses. The tolerability and safety profile of DESV at this dose is very favourable, a fact that is associated with a minimal impact on the cytochrome P450 system which gives it the additional advantage of a lower risk of pharmacokinetic interactions. This review provides a summary of the pharmacological data of DESV, as well as the pre-clinical and clinical results on its efficacy and safety.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: PsiquiatrÃa Biológica - Volume 20, Issues 1â2, JanuaryâJune 2013, Pages 2-7
Journal: PsiquiatrÃa Biológica - Volume 20, Issues 1â2, JanuaryâJune 2013, Pages 2-7
نویسندگان
NarcÃs Cardoner Álvarez,